FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

D.C. 20549	OMB APPROVAL

OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*			2. Issuer Name and Ticker or Trading Symbol Outlook Therapeutics, Inc. [OTLK]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)							
THURMAN RANDY H				Outdook Therapeades, me. [OTEK]								X	Director			10% Ow	ner	
(Last)	(F	First)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year)							-		Officer (below)	give title		Other (s below)	pecify
C/O OUTLOOK THERAPEUTICS, INC.				07/17/2020														
4260 US	ROUTE 1																	
				4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable						
(Street)													Line)					
MONMO	OUTH N	II	08852										X				rting Person	
JUNCTIO	ON I	NJ	00032											Form file Person	ed by Mor	e than	One Report	ing
(City)	2)	State)	(Zip)															
		Та	ble I - Non	-Deriva	tive S	ecuritie	s Ac	quired,	Dis	posed c	f, or B	enefici	ally	Owned				
1. Title of Security (Instr. 3) 2. Transa Date (Month/D					Execution Date		Date,	, Transaction Disposed Code (Instr.		ities Acquired (A) or d Of (D) (Instr. 3, 4 aı			5. Amoun Securities Beneficial Owned Fo	For lly (D) ollowing (I) (: Direct Indirect str. 4) (7. Nature of Indirect Beneficial Ownership	
							Code	v	Amount	(A) (D)	or Prio	ce	Reported Transaction (Instr. 3 au	on(s)			Instr. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	Title of 2. 3. Transaction 3A. Deemed Execution Date Execution Date, or Exercise (Month/Day/Year) if any			Coc	5. Number of Derivative Securities		re es d (A) sed str.	6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Cod	le V	(A)		Date Exercisal		Expiration Date	Title	Amour or Number of Sha	er		(Instr. 4)	(S)		
Stock Option (Right to Buy)	\$1.58	07/17/2020		A		210,000		(1)	0	7/17/2030	Common Stock	210,0	000	\$0.00	210,00	00	D	

Explanation of Responses:

1. The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in full on July 17, 2021, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer through such event.

Remarks:

/s/ Lawrence Kenyon, Attorneyin-Fact 07/21/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.